Blueprint
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): June 29,
2018
Pharma-Bio
Serv, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
6 Road
696, Dorado, Puerto Rico
|
00646
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(787)
278-2709
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b2 of the Securities Exchange Act of 1934
(17 CFR §240.12b2).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On June
29, 2018, Pharma-Bio Serv, Inc. (the “Company”) held
its 2018 Annual Meeting of Stockholders. Below is a summary of the
proposals and corresponding votes.
Kirk
Michel and Dov Perlysky were elected as Class II directors to serve
for a term until the 2021 Annual Meeting of Stockholders or until
successors are duly elected and qualified. Kirk Michel and Dov
Perlysky received the following votes:
|
Nominee
|
For
|
Withheld
|
|
Kirk
Michel
|
13,852,866
|
53,000
|
|
Dov
Perlysky
|
13,852,866
|
53,000
|
There
were 4,942,634 broker non-votes on this proposal.
The
ratification of the selection of Horwath Velez & Co. PSC as the
Company's independent certified public accountants for the fiscal
year ending October 31, 2018 received the following
votes:
|
For
|
Against
|
Abstain
|
|
18,819,557
|
0
|
28,943
|
There
were no broker non-votes on this proposal.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
PHARMA-BIO SERV,
INC.
|
|
|
|
|
|
|
|
Date: June 29,
2018
|
By:
|
/s/
Pedro
J. Lasanta
|
|
|
|
|
Pedro J.
Lasanta
|
|
|
|
|
Chief Financial
Officer, Vice President Finance and
Administration and
Secretary
|
|